Recombinant Viral Antigens for Multiplex Serology Assay Development

Recombinant viral antigens for multiplex serology assay development allow researchers to evaluate antibody binding to multiple viral targets in a single experimental workflow. A well-designed panel can include antigens from different viruses, multiple proteins from one virus, strain-specific proteins or selected variants. The purchasing challenge is not simply finding each target: the antigens must also work together within the intended bead-based, planar-array or other multiplex platform. Beta LifeScience offers catalog-listed recombinant viral proteins covering coronaviruses, influenza A and B, dengue, HIV, hepatitis viruses, herpesviruses, Zika, Ebola, HPV and other viral targets. Researchers can select individual viral antigens for serology assays and feasibility studies or request technical evaluation when a project requires aligned constructs, alternative tags, specific formulations or coordinated production.

Planning a multiplex serology panel?
Review catalog viral antigens by virus, strain, sequence range, expression system, tag and purity. Submit the complete antigen list when you need help evaluating format compatibility, quantities and a coordinated quotation.

Shop Recombinant Viral Antigens
Request a Multiplex Antigen Panel Quote

This guide focuses on research-use assay development. Recombinant antigen binding alone does not establish clinical sensitivity, specificity, infection status or diagnostic performance. Any diagnostic application requires appropriate development, validation and regulatory review.

Start With the Multiplex Assay Question

A multiplex serology panel should be built around the biological question rather than the maximum number of available targets. Before ordering, define what each antigen is expected to contribute.

• Multi-pathogen screening: compare antibody binding across antigens from several viruses.
• Within-virus profiling: combine structural and nonstructural proteins to examine broader response patterns.
• Strain or subtype comparison: assess binding across selected influenza strains, dengue serotypes or other viral variants.
• Specificity assessment: include related antigens and negative controls to identify nonspecific or cross-reactive signals.
• Assay-development studies: compare antigen formats, coupling densities and dilutions before locking the panel.

These use cases require different purchasing strategies. A discovery panel may prioritize broad antigen coverage and small evaluation quantities. A downstream study may require a narrower panel, larger matched lots, tighter documentation and consistent supply.

Match the Antigen Format to the Research Requirement

This table is a starting point for product selection, not a universal format rule. Final suitability depends on the target epitopes, sample matrix and multiplex immunoassay development workflow.

Featured Recombinant Viral Antigens for Multiplex Panel Evaluation

The following Beta LifeScience products illustrate the virus coverage, expression systems, sequences and tags available across the catalog. These recombinant antigens for antibody detection are individual purchasing examples—not a prevalidated multiplex serology panel. Each protein should be qualified in the selected coupling chemistry and assay configuration.

Most featured products use an online-inquiry route. Review each current product page for construct details and available documentation, then confirm pack size, price, availability and lead time. Prices should not be hard-coded into a panel plan because quantities and ordering status may change.

Select Antigens That Answer Different Questions

More antigens do not automatically create a more informative assay. Each bead region or array position should have a defined purpose. For a multi-pathogen panel, choose antigens that provide meaningful coverage without creating unnecessary homology-driven ambiguity. For a within-virus panel, consider whether structural proteins, internal proteins and nonstructural proteins may capture different antibody-binding patterns. When comparing strains or serotypes, record the exact viral strain, accession number and sequence boundaries rather than relying only on a short target name such as “HA,” “NP” or “NS1.”

Cross-reactivity is a property of the antibody population, antigen sequence and assay configuration. Sequence similarity can guide panel design, but it cannot predict binding on its own. Include related antigens deliberately and interpret shared signals with orthogonal controls where needed.

Align Construct Variables Before Ordering

In a single-analyte ELISA, one protein can often be optimized independently. In a multiplex assay, every antigen competes within a shared experimental environment. Construct differences can therefore become a major source of uneven signal.

Perfect alignment is not always possible across a broad viral panel. The practical goal is to identify differences before purchase, then determine which variables require control or optimization.

Choose Expression Systems According to Epitope Requirements

E. coli expression can be a practical option for many internal proteins, linear-epitope studies and early feasibility work. It does not reproduce mammalian glycosylation, so suitability depends on the antigen and the antibodies being measured. Insect- and mammalian-cell systems may be preferable when conformational presentation or post-translational processing is important. However, expression host alone does not guarantee native antigen structure or assay performance. Sequence design, purification, oligomeric state, storage and immobilization can all affect antibody recognition.

For a multiplex panel, avoid assuming that every antigen must use the same host. Instead, document why each format was selected and test whether host- or tag-related signals appear in the intended sample matrix.

Plan Tags and Immobilization Together

Passive adsorption, covalent bead coupling, anti-tag capture, streptavidin–biotin capture and other immobilization approaches present antigens differently. A tag that is useful for purification may not be ideal for multiplex capture. His-tagged proteins can support convenient capture strategies, but a panel containing many His-tagged antigens should include controls for tag-reactive antibodies and capture-reagent background. GST and Fc fusion proteins can increase size or support orientation, yet they may introduce binding unrelated to the viral sequence. A tag-only or tag-matched control can help identify this effect.

When proteins carry different tags, decide whether the platform will use a common covalent-coupling method or antigen-specific capture chemistry. If a uniform orientation is essential, ask whether alternative tags or site-specific biotinylation can be evaluated through a semi-custom protein production route.

Build Controls Into the Purchase List

Controls should be ordered with the antigens rather than added after unexpected data appear. Depending on the study, consider:

• blank beads or uncoated array positions;
• buffer-only coupling controls;
• tag-only or irrelevant tag-matched proteins;
• unrelated recombinant proteins from the same expression host;
• known reactive and nonreactive research samples;
• within-run replicates and inter-plate controls;
• a dilution series to identify saturation and hook-like effects;
• singleplex measurements for selected antigens to assess multiplex interference.

If secondary antibodies or detection reagents are species- or isotype-specific, confirm their compatibility with the sample type and assay objective. Multiplex performance depends on the complete reagent system, not only the recombinant antigen.

Qualify Each Antigen Before Expanding the Panel

Begin with a small set of representative samples and evaluate every antigen individually. Titrate coupling input and sample dilution rather than using one concentration by default. Compare signal range, background, bead recovery and reproducibility. Next, combine antigens and look for changes that appear only in multiplex format. Competition is not limited to antigen–antibody binding; matrix components, detection reagents and high-abundance antibodies can also alter the response. A protein that works in ELISA should still be qualified on the final platform.

Do not interpret vendor-listed purity or an application such as “antibody ELISA” as validation of a specific multiplex assay. Product specifications support reagent selection; performance claims must come from the buyer’s intended platform, sample matrix and acceptance criteria.

Why Source Viral Antigens Through Beta LifeScience?

When comparing viral antigen suppliers, buyers should look beyond target names and review the exact constructs, purchasing pathway and customization support. Beta LifeScience provides a dedicated viral antigen collection organized across major virus families and research targets. Individual catalog pages allow researchers to compare strain, sequence range, expression system, tag, purity, formulation and available documentation before building a purchase list.

Catalog proteins can support rapid feasibility testing. Semi-custom protein production may be evaluated when an existing target requires another tag, buffer, concentration, packaging, endotoxin specification or QC configuration. Full-custom protein expression can be considered when the project requires a new sequence, strain, domain, variant or construct. These routes provide a clear path from catalog screening to custom viral antigen production without implying that every requested format is automatically feasible.

Submitting the full antigen list together helps the technical team review format compatibility, production routes, quantities and documentation requirements before preparing a quotation. Feasibility remains project-specific, especially for conformational antigens and coordinated multi-protein panels.

Choose the Right Purchasing Route

For early development, small catalog quantities may reduce upfront commitment. Once performance has been established, discuss larger quantities, lot planning and documentation before scaling the study.

Information to Include in a Multiplex Panel Request

Provide a concise project table containing:

1. virus, target protein, strain and accession number;
2. required sequence or domain boundaries;
3. preferred expression system and tag;
4. multiplex platform and immobilization chemistry;
5. sample type and research application;
6. purity, formulation, endotoxin and QC requirements;
7. quantity per antigen and expected study scale;
8. delivery schedule and documentation needs.

Also identify which variables must be aligned across the entire panel and which can vary. This distinction can make technical review faster and prevent unnecessary custom work.

FAQs

Can recombinant viral antigens be used directly in a multiplex serology assay?

They can be evaluated as candidate assay reagents, but each protein requires qualification for the selected coupling chemistry, platform and sample matrix. Catalog availability does not constitute validation for a specific multiplex method.

Should all antigens in the panel use the same expression system?

Not necessarily. The expression system should reflect the epitope and folding requirements of each target. Differences should be documented and controlled so they are not mistaken for virus-specific antibody binding.

Are full-length viral proteins always better than fragments?

No. Full-length proteins may present more epitopes, while fragments can focus the assay on selected regions and may express more reliably. Choose the construct according to the biological question and validation data.

How should tags be handled in a multiplex panel?

Compare tag identity, position and role in immobilization. Include tag-only or irrelevant tag-matched controls when tag-reactive binding could contribute to signal.

Can catalog and custom antigens be combined in one panel?

Yes, after compatibility testing. Catalog proteins can accelerate initial screening, while semi-custom or custom formats may address specific gaps. Differences in sequence, buffer, tag and host still need experimental control.

Can Beta LifeScience quote an entire viral-antigen panel?

Researchers can submit the full target list, constructs, quantities, platform and QC requirements for technical evaluation. The team can compare suitable catalog options and assess semi-custom or custom production where needed.

What should I compare when choosing viral antigen suppliers?

Compare each supplier’s available virus and strain coverage, sequence transparency, expression systems, tags, purity, formulation, documentation, lot planning and customization routes. For a multi-protein project, also ask whether the complete viral antigen panel can be reviewed together before quotation.

Build a More Purchase-Ready Multiplex Serology Panel

A useful multiplex panel combines biologically relevant targets with compatible recombinant-protein formats. Before ordering, compare viral strain, sequence boundaries, expression host, tag, formulation and available QC. Start with feasibility quantities, qualify each antigen on the intended platform and plan the scale-up route early.

Beta LifeScience catalog viral antigens provide a starting point for multi-pathogen, within-virus and strain-focused research panels. When alternative formats or coordinated production are required, submit the complete antigen list for technical evaluation and quotation.

Compare Viral Antigen Proteins
Request a Multiplex Viral-Antigen Panel Quote